Gramicidin

CHEMBL1201469 Phase 4 Aprobado Unknown
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

An antibiotic used topically to treat bacterial infections of the skin, eyes, and ears. It works by disrupting the bacterial cell membrane, causing the bacteria to die.

Mecanismo de acción

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

An antibiotic used topically to treat bacterial infections of the skin, eyes, and ears. It works by disrupting the bacterial cell membrane, causing the bacteria to die.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Gramicidin is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201469. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.